We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 56

House Energy & Commerce Committee Unanimously Approves FDA Reauthorization, Public Health Bills
  • Reed Smith LLP
  • USA
  • June 15 2017

On June 8, 2017, the Energy and Commerce Committee voted unanimously to approve an amended version of HR 2430, the FDA Reauthorization Act (FDARA) of


SAMHSA Final Rule on Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements
  • Reed Smith LLP
  • USA
  • October 3 2016

On September 27, 2016, the Substance Abuse and Mental Health Services Administration (SAMHSA) published a final rule establishing annual reporting


Senate Confirms Califf as FDA Commissioner
  • Reed Smith LLP
  • USA
  • February 25 2016

On February 24, 2016, the Senate confirmed Robert M. Califf, MD, MACC, as U.S. Food and Drug Administration Commissioner


FDA Gauges Coverage Organizations’ Interest in Connecting with Device Sponsors to Discuss Evidence Needs During Clearance Process
  • Reed Smith LLP
  • USA
  • February 24 2016

The FDA published a notice on February 24, 2016 requesting whether organizations (e.g. Insurers, health technology assessment organizations) that


Senate HELP Committee Clears Bipartisan Biomedical Innovation, Health IT Bills
  • Reed Smith LLP
  • USA
  • February 23 2016

The Senate Health, Education, Labor and Pensions (HELP) Committee has approved several bipartisan health policy bills, including health information


President Obama Signs Bill to Restrict Use of Microbeads in Cosmetics
  • Reed Smith LLP
  • USA
  • January 12 2016

President Obama has signed into law H.R. 1321, the "Microbead-Free Waters Act of 2015." The new law prohibits the manufacture, sale, or distribution


FDA to Hold Medical Device Cybersecurity Workshop (Jan 20-21)
  • Reed Smith LLP
  • USA
  • December 10 2015

As discussed on our sister Life Sciences Legal Update blog, the FDA is holding a public two-day workshop entitled “Moving Forward: Collaborative


FDA releases "Purple Book," including biosimilar products
  • Reed Smith LLP
  • USA
  • October 6 2014

The FDA's new "Purple Book" lists biological products licensed by FDA under the Public Health Service Act (the PHS Act). The publication includes


FDA meeting on biomarker development (Sept. 5)
  • Reed Smith LLP
  • USA
  • July 22 2014

On September 5, 2014, the FDA is holding a public meeting at the Washington Plaza Hotel, in Washington DC, to discuss current scientific and


FDA releases drugdevice industry social media guidance documents
  • Reed Smith LLP
  • USA
  • June 23 2014

The FDA released two draft social media guidance documents last week, describing how manufacturers, packers and distributors of prescription drugs